Targeted axillary dissection (TAD) is a relatively new breast cancer procedure. It allows surgical oncologists to specifically locate a lymph node that contained cancer before chemotherapy, remove it ...

Five-year OS was 94.4% with ALND omission vs 93.4% with completion ALND (HR 0.89), confirming non-inferiority; breast cancer–specific survival was similarly high in both arms. Inclusion of mastectomy ...

Dr. Kandace P. McGuire discusses how targeted axillary staging differs from traditional methods of staging in patients undergoing breast cancer treatment. Targeted axillary dissection is used for ...

Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node ...

Skipping standard axillary lymph node dissection led to very low rates of axillary recurrence in patients with node-positive breast cancer who became node-negative following neoadjuvant chemotherapy, ...

SAN ANTONIO -- Neoadjuvant chemotherapy that downstaged positive lymph nodes to negative led to a low rate of invasive breast cancer recurrence with either targeted axillary dissection (TAD) or ...

Response-guided axillary treatment using an approach known as the MARI protocol can safely spare many women with node-positive breast cancer from axillary lymph node dissection (ALND) after ...

Omitting completion axillary lymph node dissection does not increase risk for death for patients with clinically node-negative breast cancer, but it does significantly improve arm distress.Data from ...

This Canadian study included 111 women (median age 63 years), most of whom (90%, n=100) had invasive ductal carcinoma. Over the entire cohort, more than half (54%, n=60) underwent mastectomy and 46% ...

Future breast cancer treatment options may not only increase patients’ survival but also reduce or eliminate their need for surgery altogether, says breast cancer surgeon Sara Javid, MD, Fred ...